Dienogest
FDA-approved product (tablet, oral).
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Menorrhagia
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Pregnadien derivatives
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli33.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae37.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis30.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Dienogest with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Micafungin SodiumExisting use: Candidiasis52.4% AI-predicted activityagainst E. coli50+ registered studies
- DactinomycinExisting use: Kidney Wilms tumor, Neoplasm52.3% AI-predicted activityagainst E. coli50+ registered studies
- Irinotecan HydrochlorideExisting use: Adenocarcinoma, Cancer, Carcinoma and 4 more52.2% AI-predicted activityagainst E. coli50+ registered studies
- Ponatinib HydrochlorideExisting use: Acute lymphoblastic leukemia, Chronic myelogenous leukemia, Lymphoid leukemia and 1 more52.2% AI-predicted activityagainst E. coli50+ registered studies
- FinerenoneExisting use: Cardiovascular disease, Chronic kidney disease, Type 2 diabetes mellitus52.2% AI-predicted activityagainst E. coli50+ registered studies
- Bromocriptine MesylateExisting use: Acromegaly, Adenoma, Hyperprolactinemia and 4 more52.2% AI-predicted activityagainst E. coli50+ registered studies
- CrizotinibExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma52.0% AI-predicted activityagainst E. coli50+ registered studies
- Edoxaban TosylateExisting use: Atrial fibrillation, Deep vein thrombosis, Pulmonary embolism and 3 more52.0% AI-predicted activityagainst E. coli22 registered studies
- PimecrolimusExisting use: Atopic eczema, Eczematoid dermatitis51.9% AI-predicted activityagainst E. coli50+ registered studies
- Quizartinib DihydrochlorideExisting use: Acute myeloid leukemia, Myeloid leukemia51.8% AI-predicted activityagainst E. coli4 registered studies
- TucatinibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 6 more51.6% AI-predicted activityagainst E. coli50+ registered studies
- Dabigatran Etexilate MesylateExisting use: Atrial fibrillation, Deep vein thrombosis, Pulmonary embolism and 5 more51.4% AI-predicted activityagainst E. coli14 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Efficacy and Safety Study of an Oral Contraceptive in Healthy Females
NCT00206583 · start 2005-03
Registered record
- Registry ID
- NCT00206583
- Conditions
- Contraception
- Interventions
- EV/DNG (Qlaira, BAY86-5027, SH T00658ID)
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2005-03
- Completion
- 2007-07
- Enrolment
- 499
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionContraceptionInterventionEV/DNG (Qlaira, BAY86-5027, SH T00658ID)PhasePhase 3Registry statusCompletedStudy on Safety and Efficacy of an Oral Contraceptive in Treating Acne Papulopustulosa
NCT00280657 · start 2004-03-10
Registered record
- Registry ID
- NCT00280657
- Conditions
- Acne Vulgaris
- Interventions
- Valette; Diane; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2004-03-10
- Completion
- 2005-05-21
- Enrolment
- 1,326
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcne VulgarisInterventionValette; Diane; PlaceboPhasePhase 3Registry statusCompletedBleeding Pattern Study
NCT00302666 · start 2003-06
Registered record
- Registry ID
- NCT00302666
- Conditions
- Oral Contraceptive
- Interventions
- Valette (Dienogest/EE30, BAY86-5038); Valette (Dienogest/EE30, BAY86-5038)
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2003-06
- Completion
- 2005-02
- Enrolment
- 1,315
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOral ContraceptiveInterventionValette (Dienogest/EE30, BAY86-5038); Valette (Dienogest/EE30, BAY86-5038)PhasePhase 3Registry statusCompletedOvulation Inhibition of Two 4-phasic Oral Contraceptive Regimens
NCT00805415 · start 2003-03
Registered record
- Registry ID
- NCT00805415
- Conditions
- Ovulation Inhibition
- Interventions
- EV/DNG (Qlaira, BAY86-5027, SH T00658K); EV/DNG (SH T00658L)
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2003-03
- Completion
- 2004-02
- Enrolment
- 209
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOvulation InhibitionInterventionEV/DNG (Qlaira, BAY86-5027, SH T00658K); EV/DNG (SH T00658L)PhasePhase 2Registry statusCompletedFat Distribution in Healthy Early Postmenopausal Women
NCT00335218 · start 2002-07
Registered record
- Registry ID
- NCT00335218
- Conditions
- Healthy; Postmenopause
- Interventions
- Climodien / Lafamme (BAY86-5027); Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2002-07
- Completion
- 2004-08
- Enrolment
- 67
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy; PostmenopauseInterventionClimodien / Lafamme (BAY86-5027); PlaceboPhasePhase 4Registry statusCompleted